Long-acting beta(2)-agonists in childhood asthma: Don't change a winning team (yet)
Verberne
A A
AA
de Jongste
J C
JC
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D016535:Bronchial Hyperreactivity / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D004802:Eosinophilia / Q000188:drug therapy; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D000068759:Formoterol Fumarate; D006801:Humans; D008168:Lung / Q000187:drug effects; D000068299:Salmeterol Xinafoate
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D004983:Ethanolamines; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate